Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-482

Hi LED

Check p.123 of the 2022 annual report.

Some of the shares listed there are subject to options. See the footnotes on that page for the details

6.E Share Ownership

The table below sets forth information regarding the beneficial ownership of our ordinary shares based on 650,454,551 ordinary
shares outstanding at June 30, 2022 by each of our directors and key management personnel.

We have determined beneficial ownership in accordance with the rules of the SEC. A person has a beneficial ownership of a
security if he, she or it possesses sole or shared voting or investment power of that security, including options that are exercisable
within 60 days of June 30, 2022. Ordinary shares subject to options currently exercisable or exercisable within 60 days of June 30,
2022 are deemed to be outstanding for computing the percentage ownership of the person holding these options and the percentage
ownership of any group of which the holder is a member, however are not deemed outstanding for computing the percentage of any
other person.

Unless otherwise indicated, to our knowledge each shareholder possesses sole voting and investment power over the ordinary
shares listed. None of our shareholders has different voting rights from other shareholders. Unless otherwise indicated, the principal
address of each of the shareholders below is c/o Mesoblast Limited, Level 38, 55 Collins Street, Melbourne 3000, Australia.

Ordinary Shares
beneficially owned
Name Number %

Directors and key management personnel:

Silviu Itescu(1) 70,170,929 10.8%
William Burns(2) 249,666 *
Eric Rose(3) 186,666 *
Michael Spooner(4) 1,160,000 *
Joseph Swedish(5) 500,000 *
Shawn Tomasello(6) 200,000 *
Philip Facchina(7) 408,197 *
Philip Krause — *
Jane Bell(8) — *
All directors and key management personnel as a group
(9 persons) 72,875,458 11.2%
* Less than 1% of the outstanding ordinary shares.